Skip to main content

IBA pioneers theranostic advancements, empowering the market to produce Astatine-211

Written by Customer Service on . Posted in Public Companies.

Rigging of the Cyclone® 30 XP in Poland completed with a further two sites in Germany and France already operational

Louvain-la-Neuve, Belgium, December 12, 2023 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and of radiopharmaceutical production solutions is pleased to announce the start of the installation of a Cyclone® 30 XP in Poland. There are now three sites set to produce Astatine-211 (At-211) for oncology applications, reaffirming IBA’s leadership and innovation in the area of radiotheranostics.

The completion of the rigging in POLATOM on December 11th follows the successful commissioning of the first Cyclone® 30 XP machine in Jülich, Germany, earlier this year. Furthermore, an IBA cyclotron Cyclone® 70 XP, installed in France in 2008, has enabled multiple research programs already.

IBA and the three sites, ARRONAX (France), Forschungszentrum Jülich (Germany), and POLATOM (Poland), are active participants in COST Action 19114: A European Network Dedicated to Targeted Alpha Therapy (TAT) with At-211. This collaborative effort showcases a commitment to overcoming challenges and advancing targeted alpha therapy research.

Despite its scarcity, At-211, an alpha emitter, is used in clinical research for targeted alpha-therapies in the field of oncology to treat brain, thyroid, ovarian, breast, prostate cancer1. Beyond At-211, IBA is also pioneering novel accelerator applications for other theranostic isotopes.

“IBA is at the forefront of revolutionizing the radiotheranostics landscape by addressing critical market availability challenges of radiopharmaceuticals such as Astatine-211 and Actinium-225. The company’s groundbreaking efforts focus on ‘unlocking’ alpha emitters for theranostic applications,” said Bruno Scutnaire, President of IBA RadioPharma Solutions.

“The GIP Arronax (France) was the first institution to use the IBA multiparticle cyclotron. Since its installation in 2008, the cyclotron has enabled commercial activities, but also multiple research programs,” said Dr. Ferid Haddad, Managing Director of the GIP Arronax. “With the unique alpha beam capacity, the production of At-211 has enabled the institution and its partners to develop a better understanding of the At-211 chemistry, to develop radiolabeling methods and to conduct preclinical studies in order to prepare for clinical trials on new radiopharmaceutical for alpha-therapy,” he added.

“As a leading research institution and in our role as an international partner in the field of nuclear medicine, we are delighted to announce the successful operation of the Cyclone® 30 XP multiparticles cyclotron,” commented Professor Dr. Bernd Neumaier, Director of Institute of Neuroscience and Medicine (INM-5). “With our recent milestone of successfully directing an alpha beam onto a Bi-target, we are poised to advance our efforts in the development of At-211. This achievement solidifies the position of the INM-5 of the Forschungszentrum Jülich as a key provider of this promising alpha-emitting isotope for cancer therapies,” he added.

“At CERAD (Center of Design and Synthesis of Radiopharmaceuticals for Molecular Targeting), the strategic research infrastructure in Poland, we are delighted to add the Cyclone® 30 XP to reach our objectives,” said Prof. Renata Mikolajczak, research and cooperation manager of Radioisotope Centre POLATOM, National Center for Nuclear Research. “This cyclotron will provide us with new radiopharmaceuticals and notably the alpha emitter At-211 for local distribution”, she added.

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

CONTACTS

Soumya Chandramouli
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com

Olivier Lechien
Corporate Communication Director
+32 10 475 890
communication@iba-group.com

ICR Consilium
Amber Fennell, Lucy Featherstone
+44 (0) 20 3709 5700
IBA@consilium-comms.com

1 Astatine-211 based radionuclide therapy: Current clinical trial landscape https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859440/

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.